News

New Trial Data Show ‘Promising’ Sustained Sutimlimab Effects

Sanofi’s investigational therapy sutimlimab safely and rapidly prevents red blood cell destruction (hemolysis), increases hemoglobin levels, and reduces fatigue in adults with primary cold agglutinin disease (CAD), according to full data from Part A of the Phase 3 CARDINAL study. These therapeutic benefits were associated with a fast and…

Case Report Highlights Possible CAD, COVID-19 Link

The case of a man with COVID-19 who temporarily developed elevated levels of cold agglutinins — the self-reactive antibodies that cause cold agglutinin disease (CAD) — was described in a recent report. According to researchers, this is the third known case of elevated cold agglutinin levels documented in…